

AMENDMENTS TO THE CLAIMS

1-57. (Canceled)

58. (Previously Presented) A method for delivering a glycosaminoglycan to a subject, comprising, administering to a pulmonary tissue of a subject an unformulated dry glycosaminoglycan having a mean diameter of 1-500 microns.

59-115. (Canceled)

116. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 1-200 microns.

117. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 1-53 microns.

118. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 1-5 microns.

119. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 5-53 microns.

120. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 53-106 microns.

121. (Previously Presented) The method of claim 58, wherein the glycosaminoglycan is a heparin, a heparan sulfate, a low molecular weight heparin.

122-203. (Canceled)

204. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 10-500 microns.
205. (Canceled)
206. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 10-250 microns.
207. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 10-100 microns.
208. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 100-200 microns.
209. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 100-150 microns.
210. (Canceled)
211. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 20-53 microns.
212. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 53-75 microns.
213. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 75-106 microns.

214-222. (Canceled)

223. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 1-50 microns.

224. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 1-20 microns.

225. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 1-100 microns.

226. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 1-250 microns.

227. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 5-200 microns.

228. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 5-30 microns.

229. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a tap density of 0.01 - 0.4 g/cm³.

230. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a tap density of greater than 0.4 g/cm³.

231. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a tap density of less than 0.4 g/cm³.

232-238. (Canceled)

239. (Previously Presented) An unformulated dry glycosaminoglycan having a mean geometric diameter of 1-53 microns.

240. (Previously Presented) An unformulated dry glycosaminoglycan having a mean geometric diameter of 1-5 microns.

241. (Previously Presented) An unformulated dry glycosaminoglycan having a mean geometric diameter of 5-53 microns.

242. (Previously Presented) An unformulated dry glycosaminoglycan having a mean geometric diameter of 53-106 microns.

243. (Previously Presented) An unformulated dry glycosaminoglycan having a mean geometric diameter of 10-500 microns.

244. (Previously Presented) An unformulated dry glycosaminoglycan having a mean geometric diameter of 10-100 microns.

245. (Previously Presented) An unformulated dry glycosaminoglycan having a mean geometric diameter of 100-150 microns.

246. (Previously Presented) An unformulated dry glycosaminoglycan having a mean geometric diameter of 20-53 microns.

247. (Previously Presented) An unformulated dry glycosaminoglycan having a mean geometric diameter of 53-75 microns.

248. (Previously Presented) An unformulated dry glycosaminoglycan having a mean geometric diameter of 75-106 microns.

249. (Previously Presented) An unformulated dry glycosaminoglycan having a mean geometric diameter of 1-50 microns.

250. (Previously Presented) An unformulated dry glycosaminoglycan having a mean geometric diameter of 1-20 microns.

251. (Previously Presented) An unformulated dry glycosaminoglycan having a mean geometric diameter of 1-100 microns.

252. (Previously Presented) An unformulated dry glycosaminoglycan having a mean geometric diameter of 5-30 microns.